EP Patent

EP0879820A1 — Benzamide analogues, useful as PARP (ADP-Ribosyltransferase, ADPRT) DNA repair enzyme inhibitors

Assigned to Newcastle University Ventures Ltd · Expires 1998-11-25 · 27y expired

What this patent protects

A range of benzamide analogues consisting of 3-oxybenzamide derivatives are disclosed which can act as potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase or PARP enzyme (EC 2.4.2.30), and which thereby can provide useful therapeutic compounds for use in conjun…

USPTO Abstract

A range of benzamide analogues consisting of 3-oxybenzamide derivatives are disclosed which can act as potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase or PARP enzyme (EC 2.4.2.30), and which thereby can provide useful therapeutic compounds for use in conjunction with DNA-damaging cytotoxic drugs or radiotherapy to potentiate the effects of the latter. The compounds disclosed include certain benzoxazole-4-carboxamide compounds and in general they comprise compounds having the general structural formula I or pharmaceutically acceptable salt thereof, characterised in that    Y and X together form a bridge -Y-X- that represents the grouping       where R 5 is H, alkyl or an optionally substituted aralkyl or aryl group.

Drugs covered by this patent

Patent Metadata

Patent number
EP0879820A1
Jurisdiction
EP
Classification
Expires
1998-11-25
Drug substance claim
No
Drug product claim
No
Assignee
Newcastle University Ventures Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.